Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240710 | 0.81 | HTR6 (0.38) | — | |
| SCHEMBL2549990 | 0.76 | — | — | |
| SCHEMBL4069205 | 0.74 | — | — | |
| SCHEMBL12134121 | 0.66 | DYRK1A (0.43) | DYRK1A | |
| SCHEMBL18912147 | 0.66 | DYRK1A (0.43) | DYRK1A | |
| SCHEMBL21676902 | 0.65 | DYRK1A (0.40) | DYRK1A | |
| SCHEMBL14702325 | 0.63 | DYRK1A (0.38) | DYRK1A | |
| SCHEMBL14384307 | 0.62 | DYRK1A (0.40) | DYRK1A | |
| SCHEMBL14279000 | 0.60 | DYRK1A (0.39) | DYRK1A | |
| SCHEMBL12731929 | 0.58 | DYRK1A (0.37) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118323-A1 | ANTITUMOR BENZOYLSULFONAMIDES | MADER MARY MARGARET | 2009-05-07 | — | — | US | disclosed |
| US-7282595-B2 | Antitumor benzoylsulfonamides | ELI LILLY AND COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-20060106053-A1 | Antitumor benzoylsulfonamides | ELI LILLY AND COMPANY | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118323-A1 | ANTITUMOR BENZOYLSULFONAMIDES | HCCS, GLS2, GLS | DYRK1A 4409/4885 |
| US-20060106053-A1 | Antitumor benzoylsulfonamides | HCCS, GLS2, GLS | DYRK1A 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.